![Attralus and UTRF](https://news.tennessee.edu/wp-content/uploads/sites/2/2020/09/feat-attralus-1.jpg)
Attralus Secures Investment to Transform Treatment for Patients with Systemic Amyloidosis
A company with technology licensed from the UT Research Foundation secured $25 million to work on transformative medicines to improve the lives of patients with systemic amyloidosis.